Page last updated: 2024-08-25

methotrexate and Deafness, Transitory

methotrexate has been researched along with Deafness, Transitory in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's4 (57.14)24.3611
2020's2 (28.57)2.80

Authors

AuthorsStudies
Cho, HH; Choi, Y; Lee, S; Umugire, A1
Clay, S; Doss, J; Fang, Z; Moore, B; Musso, A; Norman, M; Prasad, P; Sheets, G; Tsien, F; Umrigar, A1
Bagatell, R; Balamuth, N; Balis, F; Fox, E; Levin, K; Segers, B; Womer, R; Zhu, Y1
Bruneau, B; Chappé, C; Gandemer, V; Robert, G; Taque, S1
Ash, S; Cohen, IJ; Issakov, J; Kollender, Y; Shkalim-Zemer, V; Toledano, H; Yaniv, I1
Grier, HE; Janeway, KA1
Benesch, M; Kerbl, R; Lackner, H; Oberbauer, R; Pakisch, B; Schwinger, W; Urban, C1

Reviews

1 review(s) available for methotrexate and Deafness, Transitory

ArticleYear
Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects.
    The Lancet. Oncology, 2010, Volume: 11, Issue:7

    Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Hearing Loss; Heart Diseases; Humans; Ifosfamide; Infertility; Kidney Diseases; Methotrexate; Neoplasms, Second Primary; Neurotoxicity Syndromes; Osteosarcoma; Survivors

2010

Trials

2 trial(s) available for methotrexate and Deafness, Transitory

ArticleYear
Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin.
    The oncologist, 2018, Volume: 23, Issue:7

    Topics: Acute Kidney Injury; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Cross-Over Studies; Doxorubicin; Female; Hearing; Hearing Loss; Humans; Kidney; Male; Methotrexate; Organic Cation Transporter 2; Osteosarcoma; Pantoprazole; Young Adult

2018
Synchronous radiochemotherapy in unfavorable brain tumors of children and young adults.
    Journal of neuro-oncology, 1998, Volume: 39, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Deafness; Disease Progression; Disease-Free Survival; Etoposide; Follow-Up Studies; Glioma; Hearing Loss; Hematologic Diseases; Humans; Ifosfamide; Infections; Life Tables; Lomustine; Medulloblastoma; Methotrexate; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Vincristine

1998

Other Studies

4 other study(ies) available for methotrexate and Deafness, Transitory

ArticleYear
Efficiency of antioxidant Avenanthramide-C on high-dose methotrexate-induced ototoxicity in mice.
    PloS one, 2022, Volume: 17, Issue:3

    Topics: Animals; Antioxidants; Apoptosis; Cell Line; Cisplatin; Hearing Loss; Methotrexate; Mice; ortho-Aminobenzoates; Ototoxicity; Reactive Oxygen Species

2022
Is Methotrexate Ototoxic? Investigating the Ototoxic Late Effects of Pediatric Cancer Treatment.
    American journal of audiology, 2023, Sep-06, Volume: 32, Issue:3

    Topics: Antineoplastic Agents; Child; Cisplatin; Deafness; Hearing Loss; Humans; Methotrexate; Neoplasms; Ototoxicity; Retrospective Studies

2023
Hearing loss during osteosarcoma chemotherapy: when acute ifosfamide toxicity revealed unnoticed methotrexate encephalopathy.
    Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:2

    Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Brain; Brain Diseases; Female; Hearing Loss; Humans; Ifosfamide; Magnetic Resonance Imaging; Methotrexate; Osteosarcoma

2014
Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Doxorubicin; Drug Substitution; Etoposide; Female; Follow-Up Studies; Hearing Loss; Humans; Ifosfamide; Kidney Diseases; Leucovorin; Male; Methotrexate; Osteosarcoma; Pilot Projects; Stroke Volume; Survival Rate; Treatment Outcome; Young Adult

2015